Not a good buy right now: price is in a clear downtrend (bearish MAs + worsening MACD), and the stock is trading below/near key support.
Short-term bounce is possible (RSI oversold + bullish call-heavy options positioning), but the upcoming earnings event creates high headline risk for an impatient entry.
Better stance today is HOLD (wait for either a confirmed reversal above ~43 pivot or a post-earnings reset); buying now is more of a speculative mean-reversion trade than a high-conviction entry.
Momentum: MACD histogram -0.882 and negatively expanding → bearish momentum is strengthening, not stabilizing yet.
RSI: RSI_6 = 29.13 (oversold/near-oversold) → increases odds of a short-term rebound, but does not by itself confirm a trend change.
Levels: Current 39.21 is below S1 (39.648), suggesting support is being tested/failed; next support S2 ~37.583. Upside reclaim level is pivot ~42.991, then resistance at 46.333.
Intellectia Proprietary Trading Signals: No signal on given stock today. (No AI Stock Picker; no SwingMax entry.)
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: Put/call ratios are low (OI PCR 0.4; Volume PCR 0.2) → positioning skews bullish (more calls vs puts).
Activity: Today’s option volume (61) is elevated vs 30-day average (141.86%), suggesting rising trader attention.
Volatility: IV_30d 77.93 vs HV 52.61 and IV percentile 97.61 → options are very expensive; market is pricing substantial near-term movement (often around events like earnings).
Takeaway: Options market is leaning bullish, but the extremely high IV implies the market expects a large move and can punish “wrong-way” entries.
Technical Summary
Sell
11
Buy
4
Positive Catalysts
Hedge funds are buying (reported buying amount +247.65% QoQ), a supportive flow signal.
Analyst support: Roth maintains Buy and calls NSP a top pick for 2026, expecting profit improvement as healthcare benefit costs ease and Workday joint-solution ramp.
Potential mean-reversion setup: oversold RSI near support can fuel a tactical bounce if the market stabilizes.
Event catalyst: Earnings on 2026-02-11 after hours can re-price the stock quickly if results/guidance surprise positively.
Neutral/Negative Catalysts
opens room to S2 (~37.
if selling continues.
with elevated IV suggests market expects volatility; downside gap risk is meaningful.
Financial Performance
Latest quarter provided: 2025/Q3.
Revenue: $1.623B, +3.97% YoY (modest growth).
Profitability: Net income -$20M (down -766.67% YoY) and EPS -0.53 (down -762.5% YoY) → sharp deterioration into a loss.
Margins: Gross margin 11.34%, down -18.83% YoY → cost pressure remains a key issue.
Overall: Top-line is growing slightly, but profitability and margins weakened materially, increasing reliance on a 2026 cost normalization thesis.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: Roth Capital kept a Buy rating but lowered its price target to $62 from $71 (2026-01-05), after having raised it to $71 from $62 (2026-01-04) — net message: still bullish long-term, but acknowledging nearer-term uncertainty/volatility.
Wall Street pros: expectation of margin/profit recovery as healthcare benefit costs ease; potential growth acceleration via Workday partnership; valuation re-rating potential back toward historical multiples if execution improves.
Wall Street cons: recent earnings/margin deterioration increases skepticism; near-term results (and guidance) remain the key gating factor; stock is technically weak despite bullish longer-term narrative.
Influential/political trading check: No recent congress trading data available; insider trend noted as neutral (no significant insider trading trends in the last month).
Wall Street analysts forecast NSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NSP is 48.5 USD with a low forecast of 35 USD and a high forecast of 62 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast NSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NSP is 48.5 USD with a low forecast of 35 USD and a high forecast of 62 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
2 Hold
1 Sell
Hold
Current: 40.280
Low
35
Averages
48.5
High
62
Current: 40.280
Low
35
Averages
48.5
High
62
Roth Capital
Jeff Martin
Buy
downgrade
$71 -> $62
AI Analysis
2026-01-05
Reason
Roth Capital
Jeff Martin
Price Target
$71 -> $62
AI Analysis
2026-01-05
downgrade
Buy
Reason
Roth Capital analyst Jeff Martin lowered the firm's price target on Insperity (NSP) to $62 from $71 and keeps a Buy rating on the shares. The firm names the stock a top pick for 2026. Insperity's profits should significantly improve in 2026 as elevated healthcare benefit costs ease. Further, the company should see a gradual ramp of middle-market clients on its joint solution with Workday (WDAY), adds Roth. The firm believes this will position Insperity for growth acceleration and margin gains in 2027 that should drive the stock's multiple back to its historical valuation of 12-15 times adjusted EBITDA.
RBC Capital
Matthew Hedberg
Outperform
downgrade
$27 -> $23
2026-01-05
Reason
RBC Capital
Matthew Hedberg
Price Target
$27 -> $23
2026-01-05
downgrade
Outperform
Reason
RBC Capital analyst Matthew Hedberg lowered the firm's price target on Netskope to $23 from $27 and keeps an Outperform rating on the shares. 2026 is likely to be a year when AI tailwinds become more evident for companies well positioned for enterprise AI adoption, while less prepared peers may remain pressured by the "AI is the death of software" narrative, the analyst tells investors in a research note. Enterprise spending appears to be stabilizing and improving in select areas, with GenAI driving innovation even as management teams remain conservative in early 2026 guidance, the firm says.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NSP
